RxDoctor Payments Data

Suwong Wongsuwan, MD

Cardiovascular Disease · Walla Walla, WANPI 1497700975

Payments from drug & device makers

$3,317in general payments, 2019–2025

Across 32 payments — averaging $103.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$324
  • Abiomed$204
  • Penumbra, Inc.$141
  • Boehringer Ingelheim$60
  • Boston Scientific$27
  • plus $14 from 1 others

What the payments were for

  • Travel & lodging$2,23167%
  • Food & beverage$1,07232%
  • Education$140%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic15$2,547
Abbott10$324
Abiomed2$204
Penumbra, Inc.1$141
Boehringer Ingelheim2$60
Boston Scientific1$27
AstraZeneca1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,317 in reported general payments places this provider in the 70th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$433,017
Medicare patients
2,358
Services billed
9,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban361$483,648
JardianceEmpagliflozin277$308,201
XareltoRivaroxaban121$145,967
EntrestoSacubitril/Valsartan132$140,648
FarxigaDapagliflozin Propanediol42$32,856
Repatha SureclickEvolocumab24$24,905
TrulicityDulaglutide17$23,379
BrilintaTicagrelor14$11,400
Praluent PenAlirocumab19$8,937
Metoprolol Succinate435$5,950
Atorvastatin Calcium520$5,652
Potassium Chloride167$4,611
Dofetilide22$3,900
Rosuvastatin Calcium196$2,823
Flecainide Acetate76$2,767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$60$308,201277 claims
AstraZenecaFarxiga, Brilinta$14$44,25656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Walla Walla

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →